Personalized Medicine: how to Switch from the Concept to the Integration into the Clinical Development Plan to Obtain Marketing Authorization

Article ID	Journal	Published Year	Pages	File Type
2579045	Thérapie	2012	9 Pages	PDF

Abstract

Moreover, business models related to the economic environment should be taken into account when deciding whether or not to retain a biomarker allowing the selection of target populations in a general population.

Keywords

FDA ROC EMA INCA EGFR NIH INR European Medicines agency Theranostic Food and Drug Administration DRESS syndrome Marketing authorization economic model genome wide association study GWAS National Institute of Health International Normalized Ratio Biomarkers Personalized medicine Epidermal growth factor receptor

Related Topics

Health Sciences Pharmacology, Toxicology and Pharmaceutical Science Pharmacology, Toxicology and Pharmaceutics (General)

Preview

Personalized Medicine: how to Switch from the Concept to the Integration into the Clinical Development Plan to Obtain Marketing Authorization

Authors

Laurent Becquemont, Régis Bordet, Dominic Cellier,